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ABSTRACT 
The reverse phase high performance liquid chromatography 
(RP-HPLC) method of Atenolol and Hydrochlorothiazide is 
individually available in United State of Pharmacopoeia-27 
(USP-27) but no reference is available for combined 
estimation of Atenolol and Hydrochlorothiazide in tablets 
formulation. The aim of our present work was to develop a 
precise and validated RP-HPLC method for the 
simultaneous determination of Atenolol and 
Hydrochlorothiazide in tablets formulation. The 
quantification was carried out by using Zorbax SB-CN (250 
x 4.6 mm), 5µm column in isocratic mode with mobile 
phase, Water: Buffer: Methanol (50:35:15). The flow rate 
was 1.2 ml/min. The peak purity of Atenolol and 
Hydrochlorothiazide were 0.999 and 1.000 respectively. 
Ruggedness and robustness of method were performed and 
the percentage relative standard deviation (RSD) was found 
below 2.0%. The percentage recovery was found in the 
range of 98% to 102% at three different levels. Calibration 
curves were linear over studies ranges with correlation co-
efficient found between the range of 0.99 to 1.00.  Sample 
and standard solution stability study was performed over 21 
h at room temperature and found stable. The percentage 
deviation was below 2.0%. 
 
KEY WORDS: Atenolol; Hydrochlorothiazide; RP-HPLC 
method; Combination Tablets. 
  
 
 
 
 
 
INTRODUCTION  
Monotherapy with various antihypertensive agents is not 
always sufficient to control the bloodpressure, and 
concomitant use of two or more drugs is necessary in 50% 
of the hypertensive patient1-4. The primary goal of any 
antihypertensive therapy is therefore achievement of 
normotension, without the addition of intolerable side 
effects, which can be accomplished by combining drug 
with different mechanism of action. A combination of 
hydrochlorothiazide and atenolol in the form of tablet or 
capsule is widely used for moderate to severe hypertension 
not controlled by a single antihypertensive agent and also 
in older patient who have low Renin levels5-8. In the 
stepped-care approach this combination is a first line 
antihypertensive drug9. Atenolol is a cardioselective beta-
adrenoreceptor blocking agent without partial agonist or 
membrane stabilizing action10. Atenolol also decreased 
Renin release from the kidney. While Hydrochlorothiazide 
is a Thiazide diuretic, act as an antihypertensive drug by 
decreasing Nacl reabsorption from the luminal side of 
epithelial cells in the distal convulated tubule by blocking 
Na/Cl transporter11. It also eventually reduced blood 
volume, reduced venous pressure and reduced preload. In 
combination with Atenolol, Hydrochlorothiazide has 
additive effect like direct vasorelaxant effect on resistance 
vessel12. Plasma half-life of Atenolol is 6-7 hrs and it is 
incompletely absorbed from gastrointestinal tract. 
Hydrochlorothiazide has plasma half-life between 5 to 15 
hrs and fairly rapidly absorbed from gastrointestinal tract, 
excreted unchanged by urine13. A co-administration of 
Atenolol with Hydrochlorothiazide produced its significant 
prolongation of half-life due to decrease in 
Hydrochlorothiazide elimination. The official monographs 
describe the procedure for individual assay of 
Hydrochlorothiazide, Atenolol as well as amiloride 
hydrochloride and Hydrochlorothiazide combination14. 
There are reports on the derivative spectrophotometric 
methods for the simultaneous determination of amiloride 
hydrochloride and hydrochlorothiazide11. However, no 
spectrophotometric method has been reported for the 
quantitative determination of Atenolol and 
Hydrochlorothiazide drugs from their combined 
formulations.  
MATERIAL AND METHODS 
Chemicals and Materials: 
Atenolol was obtained from Suchem Laboratories India and 
Hydrochlorothiazide was obtained from Ipca Laboratories 
India. Methanol, Potassium dihydrogen ortho phosphate 
and Triethyl amine (HPLC grade) were purchased from 
Spectrochem and E-Merck Limited. In-house purified 
water (USPgrade) was used throughout the study. 
Instrumentation: 
Shimadzu 2010C integrated high performance liquid 
chromatographic system was used for this experiment. 
Shimadzu 2010C system equipped with quaternary gradient 
pump, 2010C UV-VIS detector, 2010C Column Oven and 
2010C programmable auto sampler controlled by CLASS-
VP software. The Zorbax SB-CN (250X4.6 mm), 5 µm was 
used as a stationary phase. 
HPLC Condition: 
Column   Zorbax SB-CN (250X4.6 mm), 5µm 
Detector   286 nm 
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Injection volume  20 µl 
Flow rate   1.2 ml/min 
Temperature   30˚  
Run time  30 min 
Mobile phase   Water: Buffer: Methanol 
(50:35:15) 
 
Buffer preparation:  
Weigh 3.4 g potassium dihydrogen ortho phosphate in to 
1.0 l volumetric flask. Then add 2.5-ml triethylamine, 
shake well and make volume up to mark with HPLC grade 
water. Adjust pH 5.0 with dilute ortho phosphoric acid 
solution. 
Diluent:  
Use mobile phase as a diluent 
Standard preparation: 
Standard stock solutions were prepared in methanol and 
further for second dilution, dilute it with diluent to make 
final concentration Atenolol 100 µg and 
Hydrochlorothiazide 50 µg respectively. 
Sample preparation: 
Weigh accurately tablets powdered equivalent to about 125 
mg Atenolol, 62.5 mg of Hydrochlorothiazide in to 250 ml 
volumetric flask. Add about 150 ml methanol and sonicate 
it for 25 minute to dissolve. Filtered it through 0.45 µ 
HVLP nylon filter and made further dilution 5.0 ml to 50.0 
ml with mobile phase. 
RESULTS  
The detection wavelength was chosen at 286 nm for 
Atenolol and Hydrochlorothiazide in tablet dosage form 
has better absorption and sensitivity at this wavelength. 
However, to achieve the better separation of Atenolol and 
Hydrochlorothiazide in the present combination, the mobile 
phase chromatogram was shown in Fig. 1(a), (b) and (c), 
which illustrate the separation of both active ingredients in 
this system.  The isocratic HPLC method was adopted to 
analyze both components in a single run.   
System suitability and system precision: 
System suitability and system precision was daily 
performed during entire validation of this method. The 
results of system suitability and system precision were 
presented in table 1. 
Linearity and calibration curve: 
The linearity of the calibration curve was determined by 
weighed (1/c) least square regression analysis. The 
correlation coefficient was found to be 0.99 to 1.00. A 
linear relationship was found for all components. The 
results of linearity, limit of detection and limit of 
quantification were presented in table 2. 
Specificity: 
There was no interference from sample placebo and peak 
purity of Atenolol and Hydrochlorothiazide were 0.999 and 
1.000. It showed that developed analytical method was 
specific for the analysis of Atenolol and 
Hydrochlorothiazide in tablet dosage form. 
Standard and sample solution stability: 
Standard and sample solution stability was evaluated at 
room temperature for 22 h. The relative standard deviation 
was found below 2.0%. It showed that both standard and 
sample solution was stable up to 22 h at room temperature.  
Method precision: 
The precision of the method was established by carrying 
out the analysis of the analyte (n=6) using the proposed 
method. The low value of standard deviation showed that 
the method was precise. The results obtained were 
presented in table 3. 
Method accuracy: 
To ensure the reliability and accuracy of the method 
recovery studies were carried out at three different levels. 
The results of recovery studies were presented in table 4. 
Method robustness: 
Robustness of the method was determined by small 
deliberate changes in pH, flow rate, Organic phase ratio of 
mobile phase and column oven temperature. The content of 
the drug was not adversely affected by these changes as 
evident from the low value of relative standard deviation 
indicating that the method was robust. The results of 
robustness were presented in table 5. 
Method Ruggedness: 
Ruggedness test was determined between two different 
analysts, instruments and columns. The value of percentage 
RSD was below 2.0%, showed ruggedness of developed 
analytical method. The results of ruggedness were 
presented in table 6 [1], [2] and [3]. 
 
 
Table 1. 
System suitability and system precision 
 
Compound Retention time n k’  R  T α  
(Mean ± SEM) 
 
Atenolol 5.02 ± 0.0224  5818 1.01  - 1.67 -  
HCTZ  7.67 ± 0.0016  9847 2.06  9.26 1.32 2.04 
 
HCTZ= Hydrochlorothiazide, n= Theoritical plates, k’= Capacity Factor, R= Resolution, T= Asymetry  α = Selectivity 
Table 2. 
Characteristics of the analytical method derived from the standard calibration curve 
 
Compound LOD  LOQ Linearity Correlation Residual std. Slope of     
 µg/ml µg/ml range  co-efficient regression regression  
    n=(6)  µg/ml   σ  S 
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Atenolol 1.5 2.5 50 to 150 0.99999 0.43650 1.8149 
HCTZ  0.37 1.24 12.6 to 75.6 0.99999 2.20464 19.58537 
 
HCTZ= Hydrochlorothiazide, OD= Limit of detection, LOQ= Limit of quantification 
Table 3.  
Method precision 
 
Compound Concentration Retention time % Assay % RSD of    
 µg/ml Mean ± SEM Mean ± SEM    Assay   
(n=6) (n=6)  (n=6) 
 
    
Atenolol 100 5.02 ± 0.0224  97.4 ± 0.5984 1.5 
HCTZ 50  7.67 ± 0.0016 98.4 ± 0.6850 1.7  
 
HCTZ = Hydrochlorothiazide 
 
 
Table 4. 
Method accuracy 
 
Level  Drug   Drug  % Assay  % RSD of  
  Added  recovered (Mean ± SEM) Assay    (mg) 
 (mg)  (n=3)   (n=3) 
For Atenolol 
50%  125.01  124.21  99.4 ± 0.2449  0.3  
100%  249.70  248.99  99.7 ± 0.3674  0.5  
150%  374.51  374.92  100.1 ± 0.0408 0.1 
For HCTZ   
50%  31.17  31.11  99.8 ± 0.0  0.1 
100%  124.95  124.14  99.4 ± 0.1224  0.2  
150%  187.68  186.08  99.1 ± 0.0  0.1 
HCTZ = Hydrochlorothiazide 
Table 5. 
Method robustness 
Compound   % RSD in Normal and Changed condition (n=5) 
 
For Temperature % RSD Normal  % RSD (-5°C) % RSD (+5°C) 
Atenolol  0.1    0.1  0.2 
HCTZ   0.1    0.02  0.1 
For pH % RSD Normal  % RSD (-0.2 unit) % RSD (+0.2 unit) 
Atenolol  0.1    0.1  0.7 
HCTZ   0.1    0.1  0.1 
Flow Rate % RSD Normal   % RSD (-10%) % RSD (+10%) 
Atenolol  0.1    0.1  0.3 
HCTZ   0.1    0.1  0.1 
Mobile phase ratio  % RSD Normal  % RSD (-2%)  % RSD (+2%) 
Atenolol  0.1    0.2  0.1 
HCTZ   0.1    0.2  0.1 
HCTZ = Hydrochlorothiazide 
Table 6. 
Method ruggedness 
 
Compound  % Assay     % RSD of Assay 
   Mean ± SEM (n=6)    (n=6)  
Day 1  Analyst-1, Instrument-1 & Column-1 
Atenolol  97.4 ± 0.5237     1.5   
HCTZ   98.4 ± 0.5572     1.7   
Day 2  Analyst-2, Instrument-2 & Column-2 
Atenolol  97.8 ± 0.3284     0.8   
HCTZ   98.6 ± 0.1354     0.4  
 
HCTZ = Hydrochlorothiazide 
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DISCUSSION 
 
The method described enables to the 
quantification of Atenolol and Hydrochlorothiazide in film-
coated tablets. The advantages lie in the simplicity of 
sample preparation and the low costs of reagents used. The 
proposed HPLC conditions ensure sufficient resolution and 
the precise quantification of the compounds. Results from 
statistical analysis of the experimental results were 
indicative of satisfactory precision and reproducibility.    
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